{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(2)"],"submitter":["Darpo B"],"pubmed_abstract":["<h4>Introduction</h4>Pridopidine is a highly selective sigma-1 receptor (S1R) agonist in development for the treatment of Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). Pridopidine's activation of S1R enhances cellular processes that are crucial for neuronal function and survival but are impaired in neurodegenerative diseases. Human brain positron emission tomography (PET) imaging studies show that at the therapeutic dose of 45 mg twice daily (bid), pridopidine selectively and robustly occupies the S1R. We conducted concentration-QTc (C-QTc) analyses to assess pridopidine's effect on the QT interval and investigated its cardiac safety profile.<h4>Methods</h4>C-QTc analysis was conducted using data from PRIDE-HD, a phase 2, placebo-controlled trial evaluating four pridop"],"journal":["Neurology and therapy"],"pagination":["597-617"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10043059"],"repository":["biostudies-literature"],"pubmed_title":["Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose."],"pmcid":["PMC10043059"],"pubmed_authors":["Hayden MR","Cruz-Herranz A","Goldberg YP","Mehra M","Ferber G","Geva M","Kovacs R","Darpo B"],"additional_accession":[]},"is_claimable":false,"name":"Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose.","description":"<h4>Introduction</h4>Pridopidine is a highly selective sigma-1 receptor (S1R) agonist in development for the treatment of Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). Pridopidine's activation of S1R enhances cellular processes that are crucial for neuronal function and survival but are impaired in neurodegenerative diseases. Human brain positron emission tomography (PET) imaging studies show that at the therapeutic dose of 45 mg twice daily (bid), pridopidine selectively and robustly occupies the S1R. We conducted concentration-QTc (C-QTc) analyses to assess pridopidine's effect on the QT interval and investigated its cardiac safety profile.<h4>Methods</h4>C-QTc analysis was conducted using data from PRIDE-HD, a phase 2, placebo-controlled trial evaluating four pridop","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2026-07-14T21:16:09.979Z","creation":"2025-02-19T02:38:32.613Z"},"accession":"S-EPMC10043059","cross_references":{"pubmed":["36811812"],"doi":["10.1007/s40120-023-00449-w"]}}